The European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previously received at least 2 treatment regimens.
As medical experts concerned about misleading information surrounding LR-131, we’d like to make the message clear — the measure poses harm to both families experiencing tragic pregnancy complications and providers.